Vialox Limited Evidence

What It Is

Vialox is the trade name for a synthetic pentapeptide with the amino-acid sequence Gly-Pro-Arg-Pro-Ala (GPRPA), terminated as the C-terminal amide. INCI-listed as Pentapeptide-3 (occasionally written Pentapeptide-3V to disambiguate it from other pentapeptide-3 entries in older cosmetic registries), the compound was developed by the Swiss specialty-pharmaceutical house Pentapharm — now part of DSM — and is supplied to formulators internationally through Centerchem (Norwalk, Connecticut). It carries PubChem CID 11605666 and a molecular weight of approximately 495.6 daltons (C₂₁H₃₇N₉O₅), placing it well above the canonical 500-dalton heuristic cutoff for unaided percutaneous absorption.

The conceptual lineage of Vialox runs through curare and the snake-venom pharmacology of the temple pit viper, Tropidolaemus wagleri. Curare (tubocurarine) is a plant-derived neuromuscular blocker historically used by indigenous South American hunters as an arrow poison and adopted in modern anesthesia for surgical paralysis; it acts by competitive antagonism at the postsynaptic nicotinic acetylcholine receptor of skeletal muscle. The temple viper produces a family of small proline-rich peptide toxins called waglerins, which similarly block the muscle nAChR — but as much smaller, structurally tractable peptides than the larger snake α-neurotoxins of cobras and kraits (Weinstein 1991; Aiken 1992; Schmidt 1992). Pentapharm's research program designed Vialox as a minimal pentapeptide intended to capture a curare-/waglerin-like binding motif in a sequence short enough to manufacture cheaply and formulate topically.

The marketing positioning that emerged from this development was the so-called "topical Botox" category — a class of cosmetic ingredients positioned as needle-free alternatives to onabotulinumtoxin A injections. Vialox sits alongside acetyl hexapeptide-8 (Argireline; Lipotec / Lubrizol), Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate; Pentapharm), Leuphasyl (pentapeptide-18; Lipotec), and Snap-8 (acetyl octapeptide-3; Lipotec) in this category. Each of these peptides was designed to interfere somewhere along the cholinergic neuromuscular axis — Argireline / Snap-8 at the SNARE complex pre-synaptically, Syn-Ake and Vialox at the postsynaptic muscle nAChR, Leuphasyl through enkephalin pathways. They are routinely combined in multi-peptide cosmetic formulations (Schagen 2017; Pai 2017).

It is critical to be clear about what Vialox is not. It is not an FDA-approved drug. It is not a prescription medicine in any jurisdiction. There are no published peer-reviewed randomized controlled trials in journals indexed by PubMed of any finished Vialox cosmetic product. The "49% wrinkle reduction in 28 days" headline that propagates through retail product copy traces back to internal Pentapharm dossiers — instrument-based skin-replica analyses on small in-house panels — and has never appeared in an indexed, peer-reviewed publication. Several published cosmetic-peptide reviews mention Vialox by reference to the manufacturer brochure and Lupo & Cole's 2007 cosmeceutical-peptide review (Lupo 2007), but no independent confirmatory trial exists as of April 2026.

Mechanism of Action

The biological rationale for Vialox is built on competitive antagonism at the muscle-type nicotinic acetylcholine receptor — the same target hit by curare, by the snake-venom waglerin and α-bungarotoxin family, and by clinical neuromuscular blockers such as rocuronium and vecuronium. The stated mechanism is mechanistically distinct from botulinum toxin, which acts pre-synaptically by SNARE-protein cleavage and irreversible blockade of acetylcholine vesicle release. Vialox is a post-synaptic, reversible, competitive nAChR antagonist by design — directly analogous in target to classical curare-class neuromuscular blockers.

• Postsynaptic nicotinic acetylcholine receptor antagonism (claim) — Manufacturer-published in-vitro work on isolated frog rectus abdominis nerve-muscle preparations reportedly demonstrates that Pentapeptide-3 displaces acetylcholine binding and reduces evoked contraction amplitude in a concentration-dependent manner, producing a curare-like dose-response profile. This is the central pharmacological CLAIM that anchors all downstream cosmetic positioning. The supporting data are summarized in Pentapharm / Centerchem technical literature; independent peer-reviewed replication on isolated muscle preparations using a synthesized GPRPA-NH₂ reference compound is not abundant in the indexed literature.
• Curare / d-tubocurarine pharmacological analogy — d-tubocurarine and related plant-derived alkaloids are the historical reference standard for postsynaptic muscle nAChR competitive antagonism, used pharmacologically since the mid-twentieth century in surgical anesthesia. Vialox is positioned as a curare-mimetic — a small synthetic peptide that occupies the acetylcholine binding pocket on the α-subunit of the muscle nAChR (α1₂βδε in adult endplates) without intrinsic agonist activity, blocking sodium-ion channel opening and preventing muscle-cell depolarization (Pai 2017; Schagen 2017).
• Waglerin pharmacology as design template — The waglerins are 22–24-residue proline-rich peptide toxins from temple pit viper venom that block the muscle nAChR with selectivity for the ε-subunit-containing adult endplate receptor (Weinstein 1991; Aiken 1992; Tsai 1995). Smaller related neurotoxic-peptide motifs from this family inspired both Pentapharm's Vialox program and the Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate) program. Vialox is the more aggressively curare-themed of the two.
• Distinction from botulinum toxin (BoNT-A) — Botulinum toxin acts pre-synaptically: the protease light chain cleaves the SNARE proteins (SNAP-25 for BoNT-A) inside the motor-nerve terminal, irreversibly blocking acetylcholine vesicle fusion and exocytosis for the ~3-month lifetime of the affected nerve terminal. Vialox is post-synaptic, reversible, and competitive — its pharmacology resembles a tiny synthetic curare more than a clostridial neurotoxin. Acetyl hexapeptide-8 / Argireline acts pre-synaptically by mimicking the SNAP-25 N-terminus and disrupting SNARE complex assembly (Blanes-Mira 2002) — closer mechanistically to BoNT than Vialox is.
• Reversibility — Competitive nAChR antagonism is concentration- and time-reversible by definition: removing the antagonist allows acetylcholine binding to resume normally as the antagonist dissociates. This is biologically and cosmetically meaningful because it implies any clinical effect from Vialox would wash out within hours of cessation, rather than persisting for months as with botulinum toxin or weeks as with the SNAP-25-disrupting peptides.
• Transdermal penetration as the rate-limiting step — A 495-dalton hydrophilic, multiply charged pentapeptide is a poor candidate for passive diffusion across the intact stratum corneum. The classical "500-dalton rule" for percutaneous absorption is a soft heuristic, not a hard cutoff, but pentapeptides of this size routinely show single-digit-percent or sub-percent cumulative permeation in Franz-cell studies on human skin without permeation enhancers. Even Argireline (a smaller and slightly less polar hexapeptide) has been shown to permeate the stratum corneum only modestly and only with appropriate vehicle engineering (Hoppel 2015). Whether enough Vialox crosses the epidermis to reach the cutaneous neuromuscular junction at pharmacologically active concentrations is the unstated assumption of every "topical Botox" headline. Independent pharmacokinetic data on Vialox transdermal flux is sparse.
• Vehicle and formulation dependence — Manufacturer guidance recommends water-soluble, slightly acidic (pH 4–6) hydrophilic vehicles, with combinations of W/O/W multiple emulsions, liposomal carriers, and chemical penetration enhancers (caprylic / capric triglycerides, propylene glycol, ethanol cosolvents) discussed in the broader cosmetic-peptide delivery literature (Hoppel 2015; Pai 2017). Inappropriate vehicles (anhydrous balms, high-occlusion lipid bases, very alkaline pH) likely render the molecule biologically inert by either denaturation or failure of percutaneous delivery.
• Local vs systemic effect — Even taking the manufacturer's transdermal-delivery claims at face value, the intended pharmacology is purely local, restricted to the cutaneous neuromuscular endplates of the small expression-related facial muscles directly under the application site. Systemic absorption sufficient to produce off-target neuromuscular blockade is biologically implausible at cosmetic concentrations because of the molecular-size barrier and the dilution into the systemic vascular pool.

What the Research Shows

The published evidence base specific to Vialox / Pentapeptide-3 in indexed peer-reviewed literature is extremely thin. Almost everything cited as "research" in cosmetic marketing copy traces back to Pentapharm / Centerchem in-house technical dossiers — instrument-based skin-replica wrinkle-depth measurements (PRIMOS, silicon negative-replica imaging, profilometry) on small panels of female volunteers, presented in supplier brochures and conference posters but not peer-reviewed in the conventional sense. The broader cosmetic-peptide reviews summarize these manufacturer claims but do not add independent confirmatory data.

• Manufacturer in-vitro mechanism data — Pentapharm technical literature on Pentapeptide-3 reports concentration-dependent inhibition of acetylcholine-induced contraction in isolated nerve-muscle preparations (frog rectus abdominis), consistent with competitive nAChR antagonism. These studies are summarized in Pentapharm / DSM brochures and in derivative cosmetic-chemistry references; they have not been individually replicated and published as standalone peer-reviewed papers in indexed journals to the depth available for, e.g., Argireline (Blanes-Mira 2002).
• Manufacturer in-vivo wrinkle-depth claims — The widely repeated "Vialox reduces wrinkle depth by ~49% after 28 days at 5% topical concentration" figure traces to Pentapharm in-house silicon-replica skin-roughness measurements on small volunteer panels (typically n < 30) reported in supplier technical bulletins. Other figures cited in product copy include "11% average roughness reduction" and "8% average wrinkle relief reduction" from the same dossier set. These are vendor data, not peer-reviewed RCT outcomes; they have not been independently replicated in indexed publications.
• Cosmetic-peptide review coverage — Mary Lupo and Anna Cole's widely cited 2007 review of cosmeceutical peptides (Lupo 2007, Dermatol Ther 20(5):343-349) catalogues Pentapeptide-3 / Vialox as a representative neurotransmitter-affecting cosmetic peptide alongside Argireline. The review is a summary of manufacturer claims, not an independent trial. Schagen's 2017 Cosmetics review and Pai et al.'s 2017 Indian J Dermatol Venereol Leprol review do the same — they list Vialox in the neurotransmitter-inhibitor category, describe the curare-mimetic mechanism, and note the absence of robust RCT data.
• Argireline as the comparator with actual published evidence — Vialox's mechanistic neighbor, Argireline / acetyl hexapeptide-8, has actually accumulated peer-reviewed clinical evaluation: Blanes-Mira's seminal 2002 mechanism paper (PMID 18498523), Wang's 2013 randomized placebo-controlled clinical study in Chinese subjects (PMID 23417317; Am J Clin Dermatol), and a 2025 systematic review of skin permeability and efficacy (PMID 40565185). The Argireline literature is thin by pharmacological standards but vastly more developed than Vialox's. A reasonable inference is that Vialox would show similar small effect sizes if subjected to comparable trials — but this inference is not the same as evidence.
• Combination-formula evidence — The 2024 MDPI Cosmetics review on non-invasive Botox-alternative peptides (Cosmetics 11(4):118) includes Vialox in summary tables of cosmetic-peptide ingredients and notes its DSM-derived neuromuscular-mimetic positioning, but again does not cite an independent RCT. Multi-peptide finished products containing Vialox plus Argireline plus Syn-Ake plus other actives have received instrument-based open-label clinical evaluations — but these formulations cannot be used to attribute effect to Vialox specifically.
• Transdermal flux is the limiting step — The Hoppel et al. 2015 work on acetyl hexapeptide-8 emulsion delivery (PMID 25497319) is the most rigorous published study of how a cosmetic-grade neuromuscular peptide actually crosses the stratum corneum. Multiple W/O/W emulsion engineering substantially increased AH-8 permeation versus simple O/W vehicles. By extension, the cumulative percutaneous permeation of Vialox in a typical aqueous serum vehicle is likely modest at best, and almost certainly the binding constant of Vialox at the muscle nAChR plus the achievable cutaneous concentration determine whether any biological effect occurs at all.
• Snake-venom waglerin pharmacology — The published literature on the waglerins from Tropidolaemus wagleri venom (Weinstein 1991, Toxicon; Aiken 1992, PMID 1359525; Schmidt 1992, PMID 1440639; Tsai 1995, PMID 7638875) is the high-quality scientific bedrock under the cosmetic-peptide marketing layer. These papers establish that small proline-rich peptide toxins can produce potent, ε-subunit-selective nAChR blockade. They do not, however, establish that a 5-residue synthetic peptide with no disulfide architecture (Vialox) recapitulates that pharmacology with anywhere near the same affinity. Designing-down from a 22-residue toxin to a 5-residue mimetic is plausible in principle and difficult in practice; potency typically drops by orders of magnitude.

Human Data

This is the section where, for most compounds in this database, the published clinical-trial program is enumerated. For Vialox there is essentially nothing to enumerate. The honest summary:

• Zero peer-reviewed RCTs of finished Vialox products — A PubMed search across "Vialox," "Pentapeptide-3," and "Pentapeptide-3V" returns no randomized controlled trials of cosmetic formulations containing Vialox as the test article. There are no Phase I, II, or III studies because Vialox is regulated as a cosmetic ingredient, not a drug — so no trials have been required for marketing.
• Manufacturer in-house dossiers — Pentapharm / DSM and Centerchem maintain internal technical dossiers reporting wrinkle-depth reduction (instrument-based, typically PRIMOS or silicon-replica profilometry) in small open-label or vehicle-controlled panels of female volunteers aged roughly 30–60 applying 5% Vialox in a hydrophilic serum vehicle twice daily. The headline figure from these dossiers is the widely repeated "49% wrinkle reduction in 28 days" — a number that enters retail copy without qualification but which has not been published in an indexed peer-reviewed journal under that exact methodology. The dossiers also report ~11% average skin-roughness reduction and ~8% average wrinkle-relief reduction across larger pooled vendor panels.
• Comparison to Argireline's published clinical base — The most directly comparable peptide, acetyl hexapeptide-8 / Argireline, has at least: Blanes-Mira 2002 — original mechanism paper, in vitro plus small in vivo cosmetic evaluation, Int J Cosmet Sci 24(5):303-310, PMID 18498523; Wang 2013 — randomized placebo-controlled clinical evaluation of Argireline in 60 Chinese subjects, Am J Clin Dermatol 14(2):147-153, PMID 23417317; and a 2025 systematic review of skin permeability and efficacy, PMID 40565185. Vialox has none of these. Argireline-class evidence is itself modest, heterogeneous, and not always positive — but it exists. Vialox's evidence base is, by comparison, an absence.
• Reasonable inference vs evidence — Mechanism-level plausibility plus a ~5%-typical topical concentration in a hydrophilic vehicle, applied chronically to small expression-related facial muscles, plausibly produces a small reduction in dynamic-wrinkle visibility. This inference is consistent with the broader cosmetic-peptide literature (Lupo 2007; Schagen 2017; Pai 2017). It is, however, an inference. Treat the absence of a published independent RCT not as a guarantee of failure but as the actual evidence state — uncertainty.
• What an honest published trial would look like — A double-blind vehicle-controlled randomized trial of a 5% Vialox serum versus a vehicle-matched placebo, applied twice daily for 12–16 weeks, with primary endpoint of crow's-foot wrinkle depth at rest and during maximum smile by independent profilometry, plus blinded photographic assessment by board-certified dermatologists, in n > 60 per arm. No such study has been published as of April 2026.

Dosing from the Literature

Vialox is a cosmetic raw material formulated into finished topical products. There is no therapeutic dose because there is no therapeutic indication. The "dosing" guidance below summarizes manufacturer formulation recommendations and the typical use ranges seen in commercial finished products.

Reconstitution & Storage

Vialox is supplied to formulators as a powder (raw peptide) or as a pre-dissolved aqueous concentrate. The following guidance summarizes manufacturer technical-bulletin storage and handling parameters typical of a hydrophilic short-chain cosmetic peptide:

• Raw material handling — Weigh under desiccated conditions; rapidly transfer to dissolution vehicle. Avoid prolonged exposure to ambient humidity, which causes lump formation and complicates dissolution.
• Formulation phase order — Add Vialox in the cool-down phase of emulsion manufacturing (typically below 40°C) after the bulk emulsion has been formed, to avoid thermal degradation of the peptide.
• Preservation — Aqueous Vialox-containing formulations require broad-spectrum cosmetic preservation; phenoxyethanol-ethylhexylglycerin combinations or sodium benzoate plus potassium sorbate are typical. Avoid formaldehyde-releasing preservatives where peptide stability matters.
• Penetration enhancement — Multiple W/O/W emulsions, liposomal delivery systems, and chemical penetration enhancers (propylene glycol, ethanol cosolvents at <10%) have been evaluated for related cosmetic peptides such as acetyl hexapeptide-8 (Hoppel 2015) and are conceptually applicable to Vialox formulation. Independent published transdermal-flux data specific to Vialox is sparse.

→ Use the Kalios Dosing Calculator for cosmetic concentration math

Side Effects & Risks

Vialox is generally regarded as low-risk in topical cosmetic use, primarily because the molecular size of the peptide and the modest cosmetic concentrations limit how much active material reaches biologically relevant compartments. The honest risk landscape:

• Minimal systemic absorption — A 495-dalton hydrophilic peptide applied at 1–5% in a hydrophilic vehicle to intact facial skin does not, by any plausible accounting, reach systemic circulation at concentrations relevant for systemic neuromuscular blockade. The molecular-size and polarity barrier across the stratum corneum is the limiting factor; only a small fraction of applied dose crosses, and that small fraction is rapidly diluted into the cutaneous capillary bed and from there into the systemic vascular pool. Theoretical systemic curare-mimetic toxicity is not biologically plausible at cosmetic concentrations.
• Local irritation and sensitization potential — Like most cosmetic peptides, Vialox can produce contact irritation in a subset of users — typically erythema, mild burning or stinging, occasional pruritus during the first weeks of use. True allergic contact dermatitis (delayed Type IV hypersensitivity) is reported anecdotally in cosmetic-pharmacology dermatology practice but is not well quantified for Vialox specifically. Patch testing prior to full-face use is reasonable for individuals with known peptide-product sensitivities.
• Vehicle-related reactions — Many adverse cosmetic reactions are driven by formulation excipients (preservatives, surfactants, fragrance, retinoid co-actives) rather than by the active peptide itself. A reaction to a Vialox-containing finished product cannot be attributed to Vialox without ingredient-by-ingredient consideration.
• Periocular use caution — Application near the eyes (for crow's-feet) carries general cosmetic-formulation risks (mucosal irritation if product migrates into the eye). Vialox-specific ocular toxicity is not characterized in published literature; standard precautions apply.
• Pregnancy and lactation — No published safety data exist on Vialox in pregnancy or lactation. The molecular-size barrier limits systemic absorption, but in the absence of explicit pregnancy-safety data, prudent practice is to defer cosmetic-peptide use during pregnancy and lactation, as it is for most actives without a specific safety dossier. Discuss with a licensed healthcare provider.
• Pediatric use — Not indicated. Vialox is a cosmetic anti-aging ingredient with no rationale for use in children or adolescents.
• Drug interactions — None established or biologically expected from a topical cosmetic peptide of this molecular size and route. Theoretical local interactions with co-applied retinoids, AHAs, BHAs, vitamin C serums, or peptide blends typically reflect formulation-pH or stratum-corneum-disruption effects rather than direct molecular interaction with Vialox.
• Combination with botulinum toxin injections — Some cosmetic dermatology practitioners combine topical neuromuscular peptides with periodic BoNT-A injections (intended either as a "bridging" maintenance application between injections or as a complementary therapy for fine static lines that BoNT does not address). There is no rigorous published evidence that Vialox enhances or prolongs the BoNT effect; the marketing claim that topical peptides "extend Botox results" is poorly characterized in indexed literature and should not be relied upon as evidence-based.
• Quality and identity assurance — As with any peptide raw material, supplier provenance, certificate of analysis, mass-spec confirmation of molecular weight, and HPLC purity documentation matter. Counterfeit or low-purity Vialox supplied via grey-market raw-material channels may contain unknown contaminants. Use only formulators who source from established suppliers (Centerchem, DSM Personal Care) with documented quality control.
• Theoretical worst-case scenario — In a hypothetical scenario of massive systemic exposure (e.g., gross misuse such as oral ingestion, intravenous injection, or application of pharmaceutical-grade concentrations across large body surface areas with damaged skin barrier), the receptor-level pharmacology predicts curare-class neuromuscular weakness — flaccid paralysis affecting respiratory and skeletal muscles, requiring ventilatory support. This is a paper risk, not an observed clinical event, and is biologically extremely unlikely at any reasonable cosmetic use case.

Bloodwork & Monitoring

Vialox is a topical cosmetic ingredient with negligible systemic absorption. There is no clinical rationale for systemic laboratory monitoring in routine cosmetic use:

• No routine bloodwork required — Unlike injectable peptides on this database (which require CMP, CBC, lipid, and indication-specific marker monitoring), topical Vialox in a properly formulated cosmetic vehicle does not warrant systemic laboratory follow-up.
• Local skin assessment — Track cosmetic outcomes with consistent same-conditions photography (same camera, same lighting, same makeup-free state) at baseline, week 4, week 8, week 12. Subjective wrinkle improvement is highly susceptible to placebo, framing, and lighting effects; a simple before/after photo protocol is the minimum honest standard for personal-use evaluation.
• Allergic / irritation surveillance — Note any erythema, pruritus, burning, or rash during the first two weeks of use. Discontinue if symptoms develop or persist; consult a dermatologist if dermatitis occurs.
• Combination with prescription topicals — If using Vialox alongside prescription retinoids (tretinoin, adapalene), prescription anti-aging compounds, or recent in-office procedures (laser resurfacing, microneedling, peels), check with the prescribing dermatologist to confirm the formulation does not exacerbate barrier disruption.
• If patch testing is desired — Apply a small amount of finished product to the forearm twice daily for 5–7 days before initiating full-face use. This is standard cosmetic-introduction practice for users with sensitive skin or prior cosmetic reactions.

Commonly Stacked With

Vialox is rarely the only "active" in a finished cosmetic product. It is most often combined with other neuromuscular-mimetic cosmetic peptides for additive or complementary mechanism coverage, plus standard skincare actives.

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

Cosmetic peptides that aim at the same neuromuscular-junction pharmacology:

Next Steps

Key References

1. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. doi:10.1046/j.1467-2494.2002.00153.x. PMID: 18498523. (Foundational mechanism paper for the SNAP-25-inhibiting cosmetic peptide Argireline; the closest analog with actual peer-reviewed mechanism evidence.)
2. Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. doi:10.1111/j.1529-8019.2007.00148.x. PMID: 18045359. (Widely cited dermatology review that catalogues Pentapeptide-3 / Vialox alongside Argireline as neurotransmitter-affecting cosmetic peptides.)
3. Pai VV, Bhandari P, Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9-18. doi:10.4103/0378-6323.186500. PMID: 27451932. (2017 review of cosmetic peptides including discussion of neurotransmitter inhibitors and curare-mimetic peptides.)
4. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016. (MDPI Cosmetics review of the cosmetic-peptide landscape including Pentapeptide-3 / Vialox; not PubMed-indexed but widely cited.)
5. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. doi:10.3389/fchem.2020.572923. (Front Chem 2020 review covering the cosmetic-peptide categories — neurotransmitter inhibitors, signal peptides, carrier peptides — with reference to Vialox.)
6. Hoppel M, Reznicek G, Kählig H, Kotisch H, Resch GP, Valenta C. Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. Eur J Pharm Sci. 2015;68:27-35. doi:10.1016/j.ejps.2014.11.014. PMID: 25497319. (The most rigorous published transdermal-delivery study of a cosmetic neuromuscular peptide; methodologically applicable to Vialox formulation.)
7. Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-153. doi:10.1007/s40257-013-0009-9. PMID: 23417317. (Randomized placebo-controlled clinical evaluation of a cosmetic neuromuscular peptide — the kind of trial that Vialox does not have.)
8. Reszko AE, Berson D, Lupo MP. Cosmeceuticals: practical applications. Obstet Gynecol Clin North Am. 2010;37(4):547-569,viii. doi:10.1016/j.ogc.2010.09.006. PMID: 21093749. (Practical clinical-dermatology overview of cosmeceutical peptide categories with reference to Vialox-class neuromuscular peptides.)
9. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26050778. (Reference for the major cosmetic carrier peptide commonly stacked with Vialox; demonstrates the higher publication standard available for better-studied cosmetic peptides.)
10. Mlosek RK, Migda B, Skrzypek E, Słoboda K, Migda M. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025. PMID: 40565185. (2025 systematic review of permeability and efficacy for the closest mechanistic neighbor to Vialox.)
11. Weinstein SA, Schmidt JJ, Bernheimer AW, Smith LA. Characterization and amino acid sequences of two lethal peptides isolated from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1991;29(2):227-236. doi:10.1016/0041-0101(91)90107-3. (Original characterization of the waglerin neurotoxic peptides — the snake-venom inspiration for the Vialox / Syn-Ake design programs.)
12. Aiken SP, Sellin LC, Schmidt JJ, Weinstein SA, McArdle JJ. A novel peptide toxin from Trimeresurus wagleri acts pre- and post-synaptically to block transmission at the rat neuromuscular junction. Pharmacol Toxicol. 1992;70(5 Pt 1):339-343. PMID: 1359525. (Mechanism characterization of waglerin-class peptides at the neuromuscular junction.)
13. Schmidt JJ, Weinstein SA, Smith LA. Molecular properties and structure-function relationships of lethal peptides from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1992;30(9):1027-1036. doi:10.1016/0041-0101(92)90048-a. PMID: 1440639. (Structure-function characterization of waglerins; the literature underpinning Vialox's design rationale.)
14. Tsai MC, Hsieh WH, Smith LA, Lee CY. Effects of waglerin-I on neuromuscular transmission of mouse nerve-muscle preparations. Toxicon. 1995;33(3):363-371. doi:10.1016/0041-0101(94)00158-5. PMID: 7638875. (Functional characterization of waglerin-I at the muscle-type nAChR — direct pharmacological precedent for the Vialox design.)
15. Tan CH, Tan KY, Yap MK, Tan NH. Venomics of Tropidolaemus wagleri, the sexually dimorphic temple pit viper: Unveiling a deeply conserved atypical toxin arsenal. Sci Rep. 2017;7:43237. doi:10.1038/srep43237. (Modern venomics characterization of the temple pit viper venom containing the waglerin neurotoxic peptides relevant to Vialox / Syn-Ake design.)
16. Park JH, Choi SH, Park SJ, Lee YJ, Park JW, Song PH, Cho CM, Ku SK, Song CH. Sustainable Dynamic Wrinkle Efficacy: Non-Invasive Peptides as the Future of Botox Alternatives. Cosmetics. 2024;11(4):118. doi:10.3390/cosmetics11040118. (2024 review summarizing the topical neuromuscular-peptide landscape including Vialox / Pentapeptide-3 in the DSM-derived ingredient summary tables.)
17. Centerchem Inc. Vialox® Pentapeptide-3 — Technical Data Sheet. Norwalk, CT: Centerchem; 2017 (and subsequent technical bulletins). (Primary manufacturer technical literature describing in-vitro and in-vivo claims; cited here as the documented source of widely repeated wrinkle-reduction percentages — vendor data, not peer-reviewed RCT data.)
18. DSM Personal Care / Pentapharm. Pentapeptide-3 (Vialox PT) — Product Brochure. Basel, Switzerland: DSM; 2018 (and subsequent revisions). (Manufacturer brochure documenting Pentapharm in-house clinical evaluation methodology; the underlying source of the "49% wrinkle reduction" headline.)
19. National Center for Biotechnology Information. PubChem Compound Summary for CID 11605666 — Vialox Peptide (Pentapeptide-3). Bethesda, MD: NCBI; accessed April 2026. (Reference for molecular identity: C₂₁H₃₇N₉O₅; MW ~495.6 Da; sequence Gly-Pro-Arg-Pro-Ala-NH₂.)